LTRN vs. GLSI, ACTU, DRUG, CKPT, ADAP, PBYI, IPHA, BMEA, CDTX, and STRO
Should you be buying Lantern Pharma stock or one of its competitors? The main competitors of Lantern Pharma include Greenwich LifeSciences (GLSI), Actuate Therapeutics (ACTU), Bright Minds Biosciences (DRUG), Checkpoint Therapeutics (CKPT), Adaptimmune Therapeutics (ADAP), Puma Biotechnology (PBYI), Innate Pharma (IPHA), Biomea Fusion (BMEA), Cidara Therapeutics (CDTX), and Sutro Biopharma (STRO). These companies are all part of the "pharmaceutical products" industry.
Lantern Pharma vs.
Greenwich LifeSciences (NASDAQ:GLSI) and Lantern Pharma (NASDAQ:LTRN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, media sentiment, risk, analyst recommendations, profitability, institutional ownership and community ranking.
In the previous week, Greenwich LifeSciences had 2 more articles in the media than Lantern Pharma. MarketBeat recorded 3 mentions for Greenwich LifeSciences and 1 mentions for Lantern Pharma. Greenwich LifeSciences' average media sentiment score of 0.80 beat Lantern Pharma's score of 0.48 indicating that Greenwich LifeSciences is being referred to more favorably in the media.
Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Lantern Pharma, indicating that it is currently the more affordable of the two stocks.
Lantern Pharma's return on equity of -56.91% beat Greenwich LifeSciences' return on equity.
Greenwich LifeSciences has a beta of 1.66, meaning that its stock price is 66% more volatile than the S&P 500. Comparatively, Lantern Pharma has a beta of 1.54, meaning that its stock price is 54% more volatile than the S&P 500.
4.2% of Greenwich LifeSciences shares are owned by institutional investors. Comparatively, 28.6% of Lantern Pharma shares are owned by institutional investors. 51.7% of Greenwich LifeSciences shares are owned by insiders. Comparatively, 7.3% of Lantern Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Greenwich LifeSciences currently has a consensus target price of $38.00, suggesting a potential upside of 195.26%. Given Greenwich LifeSciences' stronger consensus rating and higher possible upside, research analysts plainly believe Greenwich LifeSciences is more favorable than Lantern Pharma.
Lantern Pharma received 5 more outperform votes than Greenwich LifeSciences when rated by MarketBeat users. Likewise, 75.00% of users gave Lantern Pharma an outperform vote while only 41.18% of users gave Greenwich LifeSciences an outperform vote.
Summary
Greenwich LifeSciences beats Lantern Pharma on 9 of the 15 factors compared between the two stocks.
Get Lantern Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for LTRN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lantern Pharma Competitors List
Related Companies and Tools
This page (NASDAQ:LTRN) was last updated on 1/21/2025 by MarketBeat.com Staff
Free LTRN Stock Alerts